Research Paper Volume 16, Issue 6 pp 5618—5633
Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy
Figure 8. Drug sensitivity analysis for high-risk TERTp-mutant gliomas. (A–C) OncoPredict analysis of drug sensitivity of TERTp-mutant gliomas. Results suggest higher sensitivity to 5-fluorouracil and gemcitabine therapies for glioma patients in the high- vs. the low-risk group. ***P < 0.001.